An email has been sent to all registered attendees with information on how to access the virtual meeting portal.

If you've already registered and haven't received the email, please check your spam folder.

If you haven't registered yet, you will receive an email with the login details after you complete your registration.

All times listed in the event are Eastern Daylight Time (EDT). We have made considerations in scheduling our programming to serve the needs of our broad, globally-based audience as much as possible.

Please note that if you cannot join the live meeting the sessions will be available on demand for 60 days after the end of the symposium.

Mano Manoharan, PhD, IS3NA President Alnylam Pharmaceuticals

Masad J. Damha, PhD, IS3NA Immediate Past President McGill University

Co-chairs: Steve Dowdy, PhD, and Laura Sepp-Lorenzino, PhD, Intellia Therapeutics

Development of Sugar-modified Oligonucleotides with Higher Enzymatic Stability Than PS Oligonucleotides Satoshi Obika, PhD, Osaka University

9.50-10.10 PNAs with Double Face: Bimodal PNAs as Templates for Supramolecular Assemblies of Nucleic Acids Krishna N. Ganesh, FNA, FASc, FTWAS, Indian Institute of Science Education and Research

10.10-10.30 Novel DNA-boron Cluster Conjugates with Two Faces Barbara Nawrot, PhD, Polish Academy of Sciences

10.30-10.50 Improved Specificity of Conjugate siRNAs Through Chemical Modification Mark K. Schlegel, PhD, Alnylam Pharmaceuticals

Yes, presentations will be available for on-demand viewing for 60 days so that you can view them at your convenience. The content of the on-demand archive is dependent on allowance from speakers to rebroadcast their presentations as part of the on-demand archive. Attendees can expect a delay of up to 24 hours for on-demand recordings to be available.

Enter your answer here

Therapeutic Nucleosides and Evolution of Oligonucleotide Synthesis Kelvin K. Ogilvie, PhD, Acadia University

While the virtual meeting will not have scheduled Poster Sessions, virtual posters will still be an integral part of the meeting and will be available for on demand viewing at your convenience.

Co-chairs: Steve Dowdy, PhD, and Laura Sepp-Lorenzino, PhD, Intellia Therapeutics

11.00-11.20

New Backbone Chemistry Enhances the Drug-like Properties of Stereopure Oligonucleotides in Preclinical StudiesPachamuthu Kandasamy, PhD, Wave Life Sciences

11.20-11.40

In Vivo Therapeutic Genome Editing via Transient Expression of CRISPR/Cas9 Rubina Parmar, PhD, Intellia Therapeutics

11.40-12.00 Oligonucleotides Based Approaches for Treatment of Chronic Hepatitis B Leonid Beigelman, PhD, Aligos Therapeutics

Chair: Piet Herdewijn, PhD, KU Leuven

10.15-10.35 Design and Therapeutic Potential of Purinergic Receptor Ligands Kenneth A. Jacobson, PhD, National Institute of Health

10.35-10.55 Discovery of Remdesivir and Beyond Joy Feng, PhD, Gilead

10.55-11.15 Rapidly Advancing Transformational Therapeutic Solutions for Patients with Severe Viral Diseases Jean-Pierre Sommadossi, PhD, Atea Pharmaceuticals

Click here to view registration fees

Co-chairs: Steve Dowdy, PhD, and Laura Sepp-Lorenzino, PhD, Intellia Therapeutics

No. The Virtual Symposium is open to both members and nonmembers, but members will benefit by paying a lower registration rate. If you wish to become a member of IS3NA, you may complete your membership application simultaneously during your meeting registration.

Chair: Victor E. Marquez, PhD, Chemical Biology Lab, NCI, NIH

11.30-11.50

The Second Dimension of the Genetic Code Thomas Carell, PhD, Ludwig-Maximilians-Universität München

11.50-12.10 Synthesis of Novel 2’-disubstituted Ribonucleoside Analogs Franck Amblard, PhD, Emory University

12.10-12.30

A de novo Nucleoside Synthesis: New Opportunities for Medicinal and Process Chemistry Robert Britton, PhD, Simon Fraser University

The submission portal is only available to registered meeting attendees. Once you register for the meeting, you will be emailed a confirmation with a link to the abstract submission portal. If you need assistance, email us at info@is3na.org.

Co-chairs: Yitzhak Tor, PhD, University of California, San Diego and Jean-Jacques Vasseur, PhD, Université de Montpellier 12.45-12.55

Lipid-oligonucleotide conjugates incorporating long-chain sulfonyl phosphoramidate groups: synthesis and biological properties Alina Derzhalova, MSc., Novosibirsk State University

12.55-13.05

Regulation of circRNA expression in cell via RNA binding small molecule Takeshi Yamada, PhD, Osaka University

13.05-13.15

5’-cap modified oligoribonucleotides with S-adenosyl-L-methionine analogs mimicking RNA 2’O-methylation transition state as original inhibitors against Dengue Rostom Ahmed-Belkacem, PhD, Université de Montpellier

13.15-13.25

Simple chemical approaches to introduce 2,6-diaminopurine and 2-aminoadenine conjugates into oligonucleotides Mimouna Madaoui, PhD, Alnylam Pharmaceuticals

13.25-13.35

Multi-functionalized gold nanoparticles for the delivery of gapmer oligonucleotides to target mutant p53 cancer cells Eduardo García-Garrido, IMDEA Nanociencia

13.35-13.45

Promoter Recognition and Processive RNA Polymerization by a Clamping RNA Polymerase Ribozyme Razvan Cojocaru, PhD, Simon Fraser University

13.45-13.55

Click and cut: Enzymatic production of targeted DNA scissors Brionna McGorman, Dublin City University

Chairs: Victor E. Marquez, PhD, Chemical Biology Lab, NCI, NIH & Piet Herdewijn, PhD, KU Leuven

No, this is an additional meeting with a brand new agenda. The meeting in Stockholm has been rescheduled and will take place August 28-31, 2022. Click here for more details.

Co-chairs:

Suzanne Peyrottes, PhD,

Université de Montpellier

and Katherine Seley-Radtke, PhD,

University of Maryland, Baltimore County

13.15-13.25

Enantioselective organocatalytic synthesis of non natural nucleosides by cross aldol addition Leticia Lafuente, PhD, Universidad Nacional de Quilmes

13.25-13.35

Triazolo nucleotide analogues as new chemotype for CD73 inhibition Rayane Ghoteimi, PhD, Université de Montpellier

13.35-13.45

Impact of Multivalency and Encapsulation of Affinity Reagents and Catalysts Brea Manuel, Emory University

13.45-13.55

Biophysical and biological evaluations of G-quadruplex thrombin binding aptamers stabilized by charge-transfer interactions Kévan Pérez de Carvasal, Université de Montpellier

13.55-14.05

2′-Fluoroarabinocytosine substitutions promote the exclusive formation of a novel TC5 dimeric structure with i-motif characteristics Roberto El-Khoury, McGill University

14.05-14.15

Investigating the impact of epitranscriptomic modifications on RNA ensembles Hala Abou Assi, PhD, Duke University

14.15-14.25

Efficient Post-Synthetic Preparation of Oligonucleotide Conjugates via One-pot Diselenide-Selenoester Ligation-Deselenization/Alkylation Christopher Liczner, MSc., Concordia University

Chair: Yitzhak Tor, PhD, University of California, San Diego

14.10-14.30 A Natural Riboswitch Scaffold with Methyltransferase Activity Ronald Micura, PhD, University of Innsbruck

14.30-14.50 RNA Functionalization via an Expanded Genetic Alphabet Stephanie Kath-Schorr, PhD, University of Cologne

Ribozyme Gene Switches for Biosensing and Regeneration Studies Maureen McKeague, PhD, McGill University

15.10-15.30 Rapid Synthesis and Delivery of Antisense Oligonucleotides Enabled by Machine Learning Bradley L. Pentelute, PhD, Massachusetts Institute of Technology

No, you must submit a new abstract for the virtual symposium.

Chair: Yitzhak Tor, PhD, University of California, San Diego

Chair: Jean-Jacques Vasseur, PhD, Université de Montpellier

14.25-14.45 Enzymatic Photocaging of Nucleic Acids: A Strategy for Controlling Methyltransferase Target Sites by Light Andrea Rentmeister, PhD, University of Münster

14.45-15.05 Stealth Fluorescence Labeling for Live-Cell Imaging in RNA-based Therapeutics Marcus Wihelmsson, PhD, Chalmers University Technology

15.05-15.25 Light as a Tool for Understanding Biological Processes Olalla Vázquez, PhD, Philipps-Universität Marburg

Yes! Please email us at info@is3na.org and we will be happy to contact you with the sponsorship prospectus.

The Stockholm IRT has been rescheduled to August 28-31, 2022. Mark your calendars and visit this website for more information.

Triumph of Nucleic Acids David Corey, PhD, UT Southwestern

Nucleosides, Nucleotides and Human Health Víctor E. Marquez, PhD, Chemical Biology Lab, NCI, NIH

Mano Manoharan, PhD, IS3NA President Alnylam Pharmaceuticals

Masad J. Damha, PhD, IS3NA Immediate Past President McGill University